Maralixibat chloride is a Small Molecule owned by Mirum Pharmaceuticals, and is involved in 26 clinical trials, of which 19 were completed, 4 are ongoing, and 3 are planned.

Maralixibat chloride is a selective inhibitor of apical sodium-dependent bile acid transporter (ASBT). The ASBT is responsible for recycling bile acids back to the liver. The drug candidate inhibits the recycling of bile acids back to the liver thereby reducing bile acid accumulation, and improving liver function.

The revenue for Maralixibat chloride is expected to reach a total of $16bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Maralixibat chloride NPV Report.

Maralixibat chloride was originated by Pfizer and is currently owned by Mirum Pharmaceuticals.

Maralixibat chloride Overview

Maralixibat chloride (Livmarli) is an anti-pruritus agent. It is formulted as solution for oral route of administration. Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.

Maralixibat chloride (SHP-625, LUM-001) is under development for the treatment of alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) type 2 in children’s, biliary atresia. It is administered orally as a solution. The drug candidate specifically targets the apical sodium-dependent bile acid transporter (ASBT).

 It was also under development for the treatment of primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).

Mirum Pharmaceuticals Overview

Mirum Pharmaceuticals is biopharmaceutical company that develops a pipeline of novel therapies for debilitating liver diseases. The company’s pipeline products include Maralixabat, minimally absorbed, orally administered investigational drug and Volixibat, a minimally absorbed agent designed to selectively inhibit ASBT. It develops products to treat rare cholestatic liver diseases that include progressive familial intrahepatic cholestasis (PFIC), alagille syndrome (ALGS), biliary atresia (BA), primary sclerosing cholangitis (PSC) and intrahepatic cholestasis of pregnancy (ICP). Mirum Pharmaceuticals is headquartered in Foster City, California, the US.

The company reported revenues of (US Dollars) US$19.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$65.4 million in FY2021, compared to an operating loss of US$104.3 million in FY2020. The net loss of the company was US$84 million in FY2021, compared to a net loss of US$103.3 million in FY2020. The company reported revenues of US$18.8 million for the third quarter ended September 2022, an increase of 7.4% over the previous quarter.

Quick View – Maralixibat chloride

Report Segments
  • Innovator (NME)
Drug Name
  • Maralixibat chloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Genetic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.